CSL (CMXHF) Change In Inventory : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is CSL Change In Inventory?

CSL's change in inventory for the quarter that ended in Dec. 2023 was $0 Mil. It means CSL's inventory stayed the same from Jun. 2023 to Dec. 2023 .

CSL's change in inventory for the fiscal year that ended in Jun. 2023 was $0 Mil. It means CSL's inventory stayed the same from Jun. 2022 to Jun. 2023 .

CSL's Total Inventories for the quarter that ended in Dec. 2023 was $5,566 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. CSL's Days Inventory for the quarter that ended in Dec. 2023 was 270.46.

Inventory Turnover measures how fast the company turns over its inventory within a year. CSL's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.67.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CSL's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.71.

CSL Change In Inventory Historical Data

The historical data trend for CSL's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Change In Inventory Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Inventory

Get a 7-Day Free Trial

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

CSL Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

CSL (OTCPK:CMXHF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CSL's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	5516	/	3722	*	365 / 2
	=	270.46

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

CSL's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	3722	/	5516
	=	0.67

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CSL's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	5516	/	7804
	=	0.71

CSL Change In Inventory Related Terms

Thank you for viewing the detailed overview of CSL's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CMXHF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.